✦ LIBER ✦

High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors

✍ Scribed by K. Neben; S. Hohaus; H. Goldschmidt; G. Egerer; M. T. Voso; A. D. Ho; R. Haas

Publisher: Springer
Year: 2000
Tongue: English
Weight: 118 KB
Volume: 79
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s002770000190

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-Term Survival and Late-Onset Compli

Long-Term Survival and Late-Onset Complications of Cancer Patients Treated With High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation

✍ Kyuhei Kohda; Sumio Sakamaki; Takuya Matsunaga; Takashi Kuga; Akihito Fujimi; Yu 📂 Article 📅 2001 🏛 Carden Jennings Publishing 🌐 English ⚖ 90 KB

Prognostic factors for patients with acu

Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation

✍ Thorsten Graef; Matthias Vaupel; Roland Fenk; Leilani Ruf; Fabian Zohren; Ulrich 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

## Abstract In this uni‐centre retrospective study, we studied 120 adults with acute myeloid leukaemia (AML) (__n__ = 88) and myelodysplastic syndrome (MDS) (__n__ = 32) who received first allogeneic HSCT to determine prognostic factors which are correlated with the outcome after myeloablative (MA)

A randomized trial of chemotherapy with

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

✍ J.-P. Glossmann; A. Josting; B. Pfistner; U. Paulus; A. Engert; German Hodgkin's 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 90 KB